Photocure Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Dan Schneider

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	6yrs
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	6yrs
Gemiddelde ambtstermijn bestuur	1.8yrs

Recente managementupdates

Recent updates

CEO

Dan Schneider

6yrs

Tenure

Mr. Daniel Schneider, also known as Dan, joined Photocure ASA since November 2018 and has been President & CEO of PhotoCure ASA since November 1, 2018. He has been Vice President of Sales at Pernix Sleep,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Daniel Schneider	President & CEO	6yrs	geen gegevens	0.37% NOK 5.0m
Erik Dahl	Chief Financial Officer	12.3yrs	geen gegevens	0.12% NOK 1.7m
David Moskowitz	Head of Investor Relations	no data	geen gegevens	geen gegevens
Anja Gossens-von der Heidt	Head of Global Human Resources	no data	geen gegevens	geen gegevens
Anders Neijber	Chief Medical Officer of Global Medical Affairs	2.2yrs	geen gegevens	geen gegevens
Tolv Hillestad	Group Controller	no data	geen gegevens	geen gegevens

6.0yrs

Gemiddelde duur

Ervaren management: Het managementteam van 0IMT is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Johanna Holldack	Independent Director	7.6yrs	geen gegevens	geen gegevens
Neal Shore	Independent Director	no data	geen gegevens	geen gegevens
Dylan Hallerberg	Independent Chairman	1.8yrs	geen gegevens	0.55% NOK 7.6m
Ghizlane Tagmouti	Director	less than a year	geen gegevens	geen gegevens
Malene Brandborg	Independent Director	no data	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van 0IMT wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw bestuur.

Photocure Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Photocure ASA Announces Board Appointments

Photocure ASA Announces Change of Board Composition

Director recently bought kr6.5m worth of stock

Insufficient new directors

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

Recent updates

Third quarter 2024 earnings released: kr0.13 loss per share (vs kr0.18 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: kr0.45 (vs kr0.16 in 2Q 2023)

New minor risk - Share price stability

Photocure ASA Announces Board Appointments

First quarter 2024 earnings released: kr0.29 loss per share (vs kr0.43 loss in 1Q 2023)

Photocure ASA Reiterates Financial Guidance for the Year 2024

Photocure ASA Announces Pivotal Trial Results and New Real-World Evidence

Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy

Full year 2023 earnings released: EPS: kr0.01 (vs kr2.66 loss in FY 2022)

Forecast breakeven date pushed back to 2025

Photocure ASA to Report Q4, 2023 Results on Feb 21, 2024

Photocure ASA Partner Asieris Announces New Drug Application Acceptance for Regulatory Review of Hexvix in China

Third quarter 2023 earnings released: kr0.18 loss per share (vs kr0.37 loss in 3Q 2022)

Photocure ASA Announces Change of Board Composition

Director recently bought kr6.5m worth of stock

Photocure Partner Asieris Confirms Hexvix Phase III Clinical Trial in China Meets Endpoint

Second quarter 2023 earnings released: EPS: kr0.16 (vs kr0.68 loss in 2Q 2022)

Photocure Partner Asieris Announces Completion of Enrollment for Hexvix Phase III Clinical Trial in China

Insufficient new directors

Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021)

Forecast breakeven date pushed back to 2024

Full year 2022 earnings released: kr2.66 loss per share (vs kr1.15 loss in FY 2021)

Photocure Asa Announces Clinical Data Presented At ASCO GU Demonstrates Reduced Risk of Recurrence in Non-Muscle Invasive Bladder Cancer with the Use of BLC

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure Asa Announces the Publication of the Study "Clinical and Economic Impact of Blue Light Cystoscopy in the Management of Nmibc At U.S. Ambulatory Surgical Centers: What Is the Site-Of-Service Disparity?" in Urologic Oncology This Week

Photocure ASA to Report First Half, 2023 Results on Aug 09, 2023

Photocure ASA Announces New Evidence Presented At the 22nd Annual Society of Urologic Oncology Meeting Demonstrating That Blue Light Cystoscopy

Third quarter 2022 earnings released: kr0.37 loss per share (vs kr0.27 loss in 3Q 2021)

Photocure Asa Announces Data Presented At the International Bladder Cancer Network (Ibcn) Meeting Demonstrate A Reduction in the Risk of Recurrence with the Use of Blc

PPhotocure ASA Announces the Commercial Availability of Karl Storz's New Blue Light System in the U.S

Photocure ASA Publishes First Results from Laser III Clinical Study in Medical Journal, European Urology

Photocure ASA Announces Continue E Supporting the Global Launch Activities of the New and Improved Blue Light Cystoscopy

Photocure ASA Appoints Anders Neijber as Chief Medical Officer, Global Medical Affairs and Clinical Development

Second quarter 2022 earnings released: kr0.68 loss per share (vs kr0.40 loss in 2Q 2021)

Photocure Asa Provides Update on Anticipated Commercial Availability of Karl Storz's New Blue Light System in the United States

Photocure ASA Presents Positive Data from the Danish National Patient Registry at the 2022 NordUrologisk Forening (NUF) Congongress in Helsinki

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on April 28, 2022.

First quarter 2022 earnings released: kr0.82 loss per share (vs kr0.57 profit in 1Q 2021)

Full year 2021 earnings released: kr1.15 loss per share (vs kr0.91 loss in FY 2020)

Photocure Announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand

Photocure ASA Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Photocure ASA Receives FDA Approval for Use in NMIBC in the U.S

Third quarter 2021 earnings released: kr0.27 loss per share (vs kr0.23 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr0.37 loss in 2Q 2020)

Photocure ASA Announces the Publication of a Study in the Journal Urologic Oncology

Asieris Announces First Patient Administration in Europe within the Phase III Clinical Trial for APL-1702 (Cevira)

Photocure ASA (OB:PHO) announces an Equity Buyback for 2,682,006 shares, representing 10% of its issued share capital.

Photocure ASA (OB:PHO) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on June 10, 2020.

Photocure ASA Suspends Guidance for 2023

Photocure ASA to Report Q3, 2021 Results on Nov 17, 2021

Asieris Pharmaceuticals and Photocure ASA Expands Strategic Partnership to Bladder Cancer Diagnosis and Surgery in Mainland China and Taiwan

Photocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan

Photocure Announces New Cevira Patent In Europe

Photocure Launches European Hexvix Operations

Photocure ASA Provides Revenue Guidance for the Year 2020

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur